Viking Therapeutics Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Viking Therapeutics is forecast to grow earnings and revenue by 2.9% and 77.3% per annum respectively. EPS is expected to grow by 6.3% per annum. Return on equity is forecast to be -23% in 3 years.
Anahtar bilgiler
2.9%
Kazanç büyüme oranı
6.3%
EPS büyüme oranı
Biotechs kazanç büyümesi | 27.1% |
Gelir büyüme oranı | 77.3% |
Gelecekteki özkaynak getirisi | -23.0% |
Analist kapsamı | Good |
Son güncelleme | 01 Nov 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Viking Therapeutics: Lots Of Positives
Oct 28Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Sep 25Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Sep 07Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Aug 30Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Jul 25We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Apr 26Viking Therapeutics: Future Weight Loss Heavyweight?
Apr 02We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Jan 09We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Sep 21Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Jun 07We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
Mar 05Viking Therapeutics: Playing Second Fiddle To Madrigal
Aug 30We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Jul 13Revisiting Viking Therapeutics
Apr 20We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Apr 12We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth
Dec 17Viking Therapeutics: Remaining Bullish And Sticking To My Plan
Aug 27Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder
Jun 17Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?
Jan 13Viking Therapeutics announces senior management appointments
Jan 06Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?
Dec 09Viking Therapeutics: Progressing Steadily, But Concerns Remain
Nov 29Kazanç ve Gelir Büyüme Tahminleri
Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
---|---|---|---|---|---|
12/31/2026 | 29 | -205 | -265 | -220 | 10 |
12/31/2025 | 2 | -171 | -201 | -158 | 11 |
12/31/2024 | N/A | -108 | -100 | -85 | 12 |
9/30/2024 | N/A | -99 | -74 | -74 | N/A |
6/30/2024 | N/A | -97 | -72 | -72 | N/A |
3/31/2024 | N/A | -94 | -55 | -55 | N/A |
12/31/2023 | N/A | -86 | -73 | -73 | N/A |
9/30/2023 | N/A | -81 | -67 | -67 | N/A |
6/30/2023 | N/A | -74 | -61 | -61 | N/A |
3/31/2023 | N/A | -72 | -63 | -63 | N/A |
12/31/2022 | N/A | -69 | -48 | -48 | N/A |
9/30/2022 | N/A | -62 | -50 | -50 | N/A |
6/30/2022 | N/A | -59 | -47 | -47 | N/A |
3/31/2022 | N/A | -57 | -47 | -47 | N/A |
12/31/2021 | N/A | -55 | -48 | -48 | N/A |
9/30/2021 | N/A | -54 | -41 | -41 | N/A |
6/30/2021 | N/A | -50 | -35 | -35 | N/A |
3/31/2021 | N/A | -44 | -28 | -28 | N/A |
12/31/2020 | N/A | -39 | -22 | -22 | N/A |
9/30/2020 | N/A | -36 | -28 | -28 | N/A |
6/30/2020 | N/A | -32 | -26 | -26 | N/A |
3/31/2020 | N/A | -31 | -26 | -26 | N/A |
12/31/2019 | N/A | -26 | -25 | -25 | N/A |
9/30/2019 | N/A | -24 | -16 | -16 | N/A |
6/30/2019 | N/A | -24 | -18 | -18 | N/A |
3/31/2019 | N/A | -23 | -17 | -17 | N/A |
12/31/2018 | N/A | -22 | -19 | -19 | N/A |
9/30/2018 | N/A | -21 | -20 | -20 | N/A |
6/30/2018 | N/A | -20 | N/A | -18 | N/A |
3/31/2018 | N/A | -19 | N/A | -17 | N/A |
12/31/2017 | N/A | -21 | N/A | -15 | N/A |
9/30/2017 | N/A | -20 | N/A | -13 | N/A |
6/30/2017 | N/A | -18 | N/A | -13 | N/A |
3/31/2017 | N/A | -16 | N/A | -12 | N/A |
12/31/2016 | N/A | -15 | N/A | -11 | N/A |
9/30/2016 | N/A | -16 | N/A | -12 | N/A |
6/30/2016 | N/A | -17 | N/A | -13 | N/A |
3/31/2016 | N/A | -21 | N/A | -11 | N/A |
12/31/2015 | N/A | -23 | N/A | -9 | N/A |
9/30/2015 | N/A | -17 | N/A | -6 | N/A |
6/30/2015 | N/A | -12 | N/A | -3 | N/A |
3/31/2015 | N/A | -27 | N/A | -2 | N/A |
12/31/2014 | N/A | -22 | N/A | -2 | N/A |
9/30/2014 | N/A | -23 | N/A | -1 | N/A |
6/30/2014 | N/A | -23 | N/A | -1 | N/A |
3/31/2014 | N/A | 0 | N/A | 0 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: VKTX is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: VKTX is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: VKTX is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: VKTX's revenue (77.3% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: VKTX's revenue (77.3% per year) is forecast to grow faster than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: VKTX is forecast to be unprofitable in 3 years.